Asset
OPAGANIB
Redhill Biopharma Ltd. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04414618 | phase2 | completed | 2020-07-02 | 2020-11-26 | RedHill Biopharma Limited | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia |
| NCT02757326 | phase1_2 | terminated | 2016-12-13 | 2019-05-01 | RedHill Biopharma Limited | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma |
| NCT04467840 | phase2_3 | completed | 2020-08-21 | 2021-07-18 | RedHill Biopharma Limited | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia |
| NCT04502069 | phase1_2 | withdrawn | 2020-08-01 | 2021-02-01 | RedHill Biopharma Limited | Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen |
FDA applications (0)
This company has no applications containing this asset.